Intraocular pharmacotherapy: specificity and safety issues

References

• West SK. Looking forward to 20/20: a focus on the epidemiology of eye diseases. Epidemiol. Rev.22(1), 64–70 (2000).
   PubMed Web of Science ®Google Scholar
• Krzystolik MG, Afshari MA, Adamis AP et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol.120(3), 338–346 (2002).
   PubMed Web of Science ®Google Scholar
• Eyetech study group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology110(5), 979–986 (2003).
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Hafiz G et al. A Phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology113(9), e1521–e1522 (2006).
   Google Scholar
• Reich SJ, Fosnot J, Kuroki A et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis.9, 210–216 (2003).
   PubMed Web of Science ®Google Scholar
• Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin. Exp. Immunol.121(3), 458–465 (2000).
   PubMed Web of Science ®Google Scholar
• D’Amico DJ, Goldberg MF, Hudson H et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina23(1), 14–23 (2003).
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Shah SM et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a Phase I clinical trial. Hum. Gene Ther.17(2), 167–176 (2006).
   PubMed Web of Science ®Google Scholar
• Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Ophthalmology114(1), 86–91 (2007).
   PubMed Web of Science ®Google Scholar
• Wong TY, Klein R, Sun C et al. Age-related macular degeneration and risk for stroke. Ann. Intern. Med.145(2), 98–106 (2006).
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst.99(16), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol. Clin. North Am.19(3), 361–372 (2006).
   PubMedGoogle Scholar
• Friedman DS, O’Colmain BJ, Munoz B et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol.122(4), 564–572 (2004).
   PubMed Web of Science ®Google Scholar
• Tezel TH, Barr CC, Kaplan HJ. Intravitreally injected anti-VEGF drugs exert a biological effect in the fellow eye. Presented at: 24th Annual Meeting of the American Society of Retina Specialists. Cannes, France, 9–13 September 2006.
   Google Scholar
• Barouch FC, Miller JW. Potential future targets for treating ocular neovascularization. Ophthalmol. Clin. North Am.19(3), 401–409 (2006).
   PubMedGoogle Scholar
• Tezel TH, Geng L, Bodek E, Kaplan HJ. Hemoglobin (Hgb) expression in human retinal pigment epithelium (RPE): a new perspective on oxygen transport to the outer retina. Presented at: The Association for Research in Vision and Ophthalmology Meeting. Ft Lauderdale, FL, USA, April 28–May 4, 2006.
   Google Scholar
• Hahn P, Milam AH, Dunaief JL. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch’s membrane. Arch. Ophthalmol.121(8), 1099–1105 (2003).
   PubMedGoogle Scholar
• Andrews NC. Disorders of iron metabolism. N. Engl. J. Med.341(26), 1986–1995 (1999).
   Google Scholar
• Kamizuru H, Kimura H, Yasukawa T, Tabata Y, Honda Y, Ogura Y. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest. Ophthalmol. Vis. Sci.42(11), 2664–2672 (2001).
   PubMed Web of Science ®Google Scholar
• Yasukawa T, Kimura H, Tabata Y et al. Active drug targeting with immunoconjugates to choroidal neovascularization. Curr. Eye Res.21(6), 952–961 (2000).
   PubMed Web of Science ®Google Scholar
• Hagemeier HH, Vollmer E, Goerdt S, Schulze-Osthoff K, Sorg C. A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues. Int. J. Cancer38(4), 481–488 (1986).
   PubMed Web of Science ®Google Scholar
• Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene23(2), 317–329 (2004).
   PubMed Web of Science ®Google Scholar
• Murciano JC, Muro S, Koniaris L et al. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood101(10), 3977–3984 (2003).
   PubMed Web of Science ®Google Scholar
• Visser CC, Stevanovic S, Heleen Voorwinden L et al. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro.J. Drug Target12(3), 145–150 (2004).
   PubMed Web of Science ®Google Scholar
• Tezel TH, Bodek E, Sonmez K et al. Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody. Ocul. Immunol. Inflamm.15(1), 3–10 (2007).
   PubMed Web of Science ®Google Scholar
• Bora PS, Hu Z, Tezel TH et al. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc. Natl Acad. Sci. USA100(5), 2679–2684 (2003).
   PubMed Web of Science ®Google Scholar
• Vives E. Present and future of cell-penetrating peptide mediated delivery systems: ‘is the Trojan horse too wild to go only to Troy?’ J. Control Release109(1–3), 77–85 (2005).
   PubMed Web of Science ®Google Scholar
• Bodek E, Sonmez K, Wang Z, Chang T, Kaplan HJ, Tezel TH. Enhanced intraocular drug delivery using DOTA-TAT multifunctional carrier core. Presented at: The Association for Research in Vision and Ophthalmology Meeting. Ft Lauderdale, FL, USA, 6–10 May 2007.
   Google Scholar
• Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin. Drug Deliv.2(2), 335–351 (2005).
   PubMed Web of Science ®Google Scholar
• Dickerson EB, Akhtar N, Steinberg H et al. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to αvβ3 integrin. Mol. Cancer Res.2(12), 663–673 (2004).
   PubMed Web of Science ®Google Scholar
• Magzoub M, Pramanik A, Graslund A. Modeling the endosomal escape of cell-penetrating peptides: transmembrane pH gradient driven translocation across phospholipid bilayers. Biochemistry44(45), 14890–14897 (2005).
   PubMed Web of Science ®Google Scholar
• Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related macular degeneration. Trends Mol. Med.10(9), 417–420 (2004).
   PubMed Web of Science ®Google Scholar
• Tezel TH, Del Priore LV, Kaplan HJ. Reengineering of aged Bruch’s membrane to enhance retinal pigment epithelium repopulation. Invest. Ophthalmol. Vis. Sci.45(9), 3337–3348 (2004).
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Safety results of two Phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol.140(4), 585–597 (2005).
   PubMed Web of Science ®Google Scholar
• Matsumoto B, Blanks JC, Ryan SJ. Topographic variations in the rabbit and primate internal limiting membrane. Invest. Ophthalmol. Vis. Sci.25(1), 71–82 (1984).
   PubMed Web of Science ®Google Scholar
• Snead MP, Snead DR, Richards AJ et al. Clinical, histological and ultrastructural studies of the posterior hyaloid membrane. Eye16(4), 447–453 (2002).
   PubMed Web of Science ®Google Scholar
• Tezel TH, Del Priore LV, Kaplan HJ. Posterior vitreous detachment with dispase. Retina18(1), 7–15 (1998).
   PubMed Web of Science ®Google Scholar
• Kumagai K, Furukawa M, Ogino N, Uemura A, Demizu S, Larson E. Vitreous surgery with and without internal limiting membrane peeling for macular hole repair. Retina24(5), 721–727 (2004).
   PubMed Web of Science ®Google Scholar
• Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res.41(11 Pt 1), 4629–4636 (1981).
   PubMed Web of Science ®Google Scholar
• de Smet MD, Kampik A, Stalmans P, Feron E, Gandorfer A, Veckeneer M. Results of the Phase II MIVI trial: microplasmin in vitrectomy patients with macular traction or macular holes. Presented at: The Combined Meeting of the Club Jules Gonin and The Retina Society. Cape Town, South Africa, 15–20 October 2006.
   Google Scholar
• Gandorfer A, Putz E, Welge-Lussen U, Gruterich M, Ulbig M, Kampik A. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br. J. Ophthalmol.85(1), 6–10 (2001).
   PubMed Web of Science ®Google Scholar
• Ulrich J, Weiershaus C, Spannagl M, Kampik A, Gandorfer A. Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders. Presented at: The Association for Research in Vision and Ophthalmology Meeting. Ft Lauderdale, FL, USA, 30 April–4 May 2006.
   Google Scholar